UnitedHealth Group reported strong third-quarter results, with revenues up 12% and adjusted EPS growing 23% year-over-year. The company raised its full-year adjusted EPS guidance to approximately $8 per share and expressed confidence in continued robust performance into 2017. Management's positive tone, along with strong operational growth and optimistic outlook, suggests a favorable short-term impact on the stock price.

[1]